The weekly time points prior to Week 6 were not powered for statistical comparison and are descriptive only. Primary endpoint was the mean change from baseline to Week 6 in the MADRS total score in the randomization phase.¹

text-body

font-whitney

weight-whitney-default

size-medium

| 19.2px

| 21px

915px

^aBaseline mean MADRS scores were 27.3 for ADT + placebo (n=178) and 26.9 for ADT + REXULTI (n=175).
^bP values are based on mixed model repeated-measures analysis.
^*P=nominal.

text-left

text-body

font-whitney

weight-whitney-default

size-footnote

| 15px

10px | 13px

Using pooled data from 3 similarly designed 6-week randomized studies, including both 2 mg and 3 mg doses, changes were evaluated in MADRS total score in patients with MDD—with and without symptoms of anxiety.^1-3,c,d

text-body

font-whitney

weight-whitney-default

size-medium

| 19.2px

16px | 19.2px

900px

container-left

Study limitations: These analyses did not assess the effect of treatment on symptoms of anxiety. Patients with anxiety symptoms had a higher MADRS total score at baseline and the effects of anxiety and illness severity on outcomes were not differentiated. Statistical adjustments were not made for multiple comparisons, potentially inflating the type 1 error rate.³

text-left

text-body

font-whitney

weight-whitney-default

size-medium

| 19.2px

900px

Adding REXULTI reduced mean MADRS total score by over 2 points in patients with MDD with or without symptoms of anxiety³:

text-left

text-body

font-whitney

weight-whitney-default

size-medium

16px | 19.2px

15px | 21px

920px

• For patients with symptoms of anxiety, the LS mean change at Week 6 between ADT + REXULTI 2-3 mg/day and ADT + placebo was -2.19 (95% CI: -3.60 to -0.78)
• For patients without symptoms of anxiety, the LS mean change at Week 6 between ADT + REXULTI 2-3 mg/day and ADT + placebo was -2.34 (95% CI: -3.58 to -1.10)

text-left

text-body

font-whitney

weight-whitney-default

size-medium

16px | 19.2px

850px | 323px

bullet-marigold-triangle

^cBaseline demographics and clinical characteristics were similar between treatment subgroups; however, patients with symptoms of anxiety were more likely to be female and have a higher MADRS total score at baseline compared with patients without symptoms of anxiety.³

text-left

text-body

font-whitney

weight-whitney-default

size-footnote

10px | 13px

920px

bullet-marigold-triangle

^dOf the patients that received an ADT plus REXULTI 2 mg, 3 mg, or placebo, 49% had symptoms of anxiety, defined as a score of ≥7 at baseline on the HAM-D anxiety/
somatization factor.³

text-left

text-body

font-whitney

weight-whitney-default

size-footnote

10px | 13px

890px

bullet-marigold-triangle

ADT, antidepressant treatment; HAM-D, Hamilton Rating Scale for Depression; LS, least squares; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, major depressive disorder; SE, standard error.

text-left

text-body

font-whitney

weight-whitney-default

size-footnote

| 16.8px

10px | 13px

930px

bullet-marigold-triangle

References: 1. Thase ME, Youakin JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76(9):1224-1231. 2. Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015;76(9):1232-1240. 3. Thase ME, Weiller E, Zhang P, Weiss C, McIntyre RS. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies. Neuropsychiatr Dis Treat. 2019;15:37-45.

text-body

font-whitney

weight-whitney-default

size-footnote

| 16.8px

11px | 15.8px

939px

container-left

hide-on-mobile reference-text